全文获取类型
收费全文 | 27294篇 |
免费 | 1621篇 |
国内免费 | 256篇 |
专业分类
耳鼻咽喉 | 235篇 |
儿科学 | 539篇 |
妇产科学 | 578篇 |
基础医学 | 2783篇 |
口腔科学 | 665篇 |
临床医学 | 1933篇 |
内科学 | 7871篇 |
皮肤病学 | 352篇 |
神经病学 | 2382篇 |
特种医学 | 1041篇 |
外科学 | 5144篇 |
综合类 | 54篇 |
一般理论 | 5篇 |
预防医学 | 999篇 |
眼科学 | 518篇 |
药学 | 1626篇 |
中国医学 | 55篇 |
肿瘤学 | 2391篇 |
出版年
2023年 | 271篇 |
2022年 | 233篇 |
2021年 | 908篇 |
2020年 | 585篇 |
2019年 | 838篇 |
2018年 | 1000篇 |
2017年 | 727篇 |
2016年 | 880篇 |
2015年 | 899篇 |
2014年 | 1218篇 |
2013年 | 1497篇 |
2012年 | 2284篇 |
2011年 | 2170篇 |
2010年 | 1250篇 |
2009年 | 1202篇 |
2008年 | 1874篇 |
2007年 | 1816篇 |
2006年 | 1704篇 |
2005年 | 1692篇 |
2004年 | 1591篇 |
2003年 | 1359篇 |
2002年 | 1223篇 |
2001年 | 120篇 |
2000年 | 118篇 |
1999年 | 150篇 |
1998年 | 164篇 |
1997年 | 137篇 |
1996年 | 129篇 |
1995年 | 149篇 |
1994年 | 123篇 |
1993年 | 119篇 |
1992年 | 88篇 |
1991年 | 55篇 |
1990年 | 66篇 |
1989年 | 50篇 |
1988年 | 40篇 |
1987年 | 36篇 |
1986年 | 42篇 |
1985年 | 38篇 |
1984年 | 34篇 |
1983年 | 33篇 |
1982年 | 50篇 |
1981年 | 28篇 |
1980年 | 27篇 |
1979年 | 18篇 |
1978年 | 12篇 |
1976年 | 11篇 |
1975年 | 8篇 |
1974年 | 12篇 |
1933年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
Giorgio Bogani Antonino Ditto Fabio Martinelli Mauro Signorelli Stefania Perotto Domenica Lorusso Francesco Raspagliesi 《Journal Of Gynecologic Oncology》2015,26(4):252-254
Endometrial cancer is the most common gynecologic malignancy in the developed countries. Although the high incidence of this occurrence no consensus, about the role of retroperitoneal staging, still exists. Growing evidence support the safety and efficacy of sentinel lymph node mapping. This technique is emerging as a new standard for endometrial cancer staging procedures. In the present paper, we discuss the role of sentinel lymph node mapping in endometrial cancer, highlighting the most controversies features. 相似文献
62.
Cardiovascular disease, including stroke, heart failure and kidney disease, has been common in sub-Saharan Africa for many years, and rapid urbanization is causing an upsurge of ischaemic heart disease and metabolic disorders. At least two-thirds of cardiovascular deaths now occur in low- and middle-income countries, bringing a double burden of disease to poor and developing world economies. High blood pressure (or hypertension) is by far the commonest underlying risk factor for cardiovascular disease. Its prevention, detection, treatment and control in sub-Saharan Africa are haphazard and suboptimal. This is due to a combination of lack of resources and health-care systems, non-existent effective preventive strategies at a population level, lack of sustainable drug therapy, and barriers to complete compliance with prescribed medications. The economic impact for loss of productive years of life and the need to divert scarce resources to tertiary care are substantial. 相似文献
63.
64.
65.
Andreana Marino Simona Pergolizzi Eugenia R. Lauriano Giuseppe Santoro Francesca Spataro Francesco Cimino Antonio Speciale Antonia Nostro Giuseppe Bisignano 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(2):163-168
The Toll‐Like Receptor 2 (TLR2) plays an active and important role in Staphylococcus aureus‐induced chronic ocular inflammation. The aim of this study was to investigate the expression and function of TLR2 of corneal stromal cells in ex vivo rabbit model of S. aureus keratitis. Corneal buttons with sclera rims placed in an ex vivo air‐interface organ culture were assigned to two groups: corneas with epithelial and stromal abrasions. Each group was then divided into two sub‐groups exposed to UV‐killed S. aureus ATCC 6538P and S. aureus ATCC 29213, respectively. TLR2 and IL‐8 mRNA expressions were analyzed by quantitative real‐time RT‐PCR. TLR2 localization was visualized by immunofluorescence analysis. The results demonstrated that TLR2 and IL‐8 mRNA were significantly expressed in the stromal cells of the groups exposed to S. aureus strains. Moreover, it has been demonstrated that, after corneal injury, keratocytes differentiated into myofibroblasts became able to express TLR2 only when exposed to S. aureus. Identification of mechanisms regulation of corneal TLRs may lead to development of therapeutic interventions aimed at controlling corneal inflammation. This ex vivo model can be used to clarify the molecular events of bacterial‐corneal tissue interactions and their inflammatory consequences. 相似文献
66.
Giammaria Fiorentini Camillo Aliberti Donatella Sarti Paolo Coschiera Massimo Tilli Luca Mulazzani Paolo Giordani Francesco Graziano Alfonso Marqués Gonzalez Raul García Marcos Fernando Gómez Mugnoz Maurizio Cantore Stefano Ricci Vincenzo Catalano Andrea Mambrini 《World journal of gastrointestinal oncology》2015,7(6):47-54
AIM: To investigate efficacy and safety of second-line treatment with irinotecan-loaded drug-eluting beads (DEBIRI) and cetuximab (DEBIRITUX) of unresectable colorectal liver metastases.METHODS: Patients with the following characteristics were included in the study: unresectable hepatic metastases from colorectal carcinoma (CRC-LM), progression after first line chemotherapy (any type of chemotherapeutic drug and combination was allowed), second line treatment (mandatory), which included for each patient (unregarding the KRas status) two cycles of DEBIRI (using 100-300 μm beads loaded with irinotecan at a total dose 200 mg) followed by 12 cycles of cetuximab that was administered weekly at a first dose of 400 mg/m2 and then 250 mg/m2; good performance status (0-2) and liver functionality (alanine aminotransferase and gamma-glutamyl transferase not exceeding three times the upper limit of normal, total bilirubin not exceeding 2.5 mg/mL). Data were collected retrospectively and included: tumor response (evaluated monthly for 6 mo then every 3 mo), overall response rate (ORR), KRas status, type and intensity of adverse events (G according to the Common Terminology Criteria for Adverse Events v3.0, CTCAE), overall survival (OS) and progression free survival (PFS).RESULTS: Forty consecutive cases of CRC hepatic metastases were included in the study. Median duration of DEBIRITUX was 4.4 mo (range, 4.0-6.5). Sixteen patients (40%) received the planned 2 cycles of DEBIRI and an average of 10 cetuximab cycles. ORR of the whole sample was 50%, in particular 4 patients were complete responders (10%) and 16 (40%) partial responders. The most observed side effects (G2) were: post-embolization syndrome (30%), diarrhea (25%), skin rushes (38%) and asthenia (35%). The retrospective evaluation of KRas status (24 wild type, 16 mutated) showed that the group of patients with wild type KRas had ORR significantly higher than mutant KRas. Median follow-up was 29 mo (8-48 range); median PFS was 9.8 mo and OS was 20.4 mo. Future randomized trials are required in this setting to establish a role for DEBIRITUX compared with systemic chemotherapy.CONCLUSION: DEBIRITUX seems to be efficacious after first line chemotherapy for the treatment of unresectable CRC-LM. 相似文献
67.
Deferasirox chelation therapy in patients with transfusion‐dependent MDS: a ‘real‐world’ report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 下载免费PDF全文
Luca Maurillo Massimo Breccia Francesco Buccisano Maria Teresa Voso Pasquale Niscola Giulio Trapè Caterina Tatarelli Ada D'Addosio Roberto Latagliata Susanna Fenu Anna Lina Piccioni Alberto Fragasso Maria A. Aloe Spiriti Marco Refrigeri Marianna Criscuolo Pellegrino Musto Adriano Venditti 《European journal of haematology》2015,95(1):52-56
Deferasirox (DFX) is an orally administered iron chelator approved for use in patients with transfusion‐dependent iron overload due to myelodysplastic syndromes (MDS). The safety and efficacy of DFX has been explored in clinical trial settings, but there is little data on unselected patients with MDS. The aim of this study was to retrospectively evaluate the safety, compliance, efficacy and effect on haematopoiesis of DFX in a large ‘real‐world’ MDS population. One hundred and eighteen patients with transfusion‐dependent MDS were treated with DFX across 11 centres in Italy. Serum ferritin levels, haematological response, dosing, adverse events and transfusion dependence were recorded at baseline, 3, 6, 12 and 24 months following initiation of treatment. DFX reduced mean serum ferritin levels from 1790 to 1140 ng/mL (P < 0.001), with 7.1% of patients achieving transfusion independence. Significant haematological improvement was seen in erythroid (17.6%), platelet (5.9%) and neutrophil counts (7.1%). Adverse events were reported in 47.5% of patients, including gastrointestinal and renal toxicity. Regression analysis showed that higher starting doses of DFX are associated with transfusion independence at 24 months. DFX is a safe, effective treatment for transfusion‐dependent MDS that can lead to transfusion independence and haematological improvement in a subset of patients. 相似文献
68.
Paola Finsinger Massimo Breccia Clara Minotti Ida Carmosino Corrado Girmenia Marta Chisini Paola Volpicelli Federico Vozella Angela Romano Chiara Montagna Gioia Colafigli Giuseppe Cimino Giuseppe Avvisati Maria Concetta Petti Francesco Lo-Coco Roberto Foà Roberto Latagliata 《Annals of hematology》2015,94(2):195-200
69.
70.